Clinical Investigation Center
VIGOR Trial: Translational approach for development of a novel oncolytic immunotherapy for osteosarcoma
Current status: Enrollment full, closed.
Principal Investigator: Jaime Modiano, VMC, PhD
Contacts: Dr. Modiano, email@example.com
Andrea Eckert, Senior Research Study Technician: 612-625-3157 or firstname.lastname@example.org
Osteosarcoma (OSA), the most common bone tumor found in the dog, has already spread by the time we diagnose 90% of the cases. Survival times are limited, from 3-4 months with surgery alone, to 9-14 months with the addition of chemotherapy. In order to improve survival in dogs, newer therapies are needed. We are studying genetically modified Vesicular Stomatitis Virus (VSV-IFNß-NIS, called VSV for short) which has been shown to be safe in a pilot study of eight dogs, and in two separate studies totaling more than 20 pet dogs with cancer.
Dogs in this study were chosen at random to have treatment with VSV or with a saline placebo. Neither the owners nor the investigators knew which treatment the dogs were given. Dogs given placebo still received the standard of care treatment of amputation and chemotherapy.
To learn more about the study, please Dr. Jaime Modiano (see above).